@article{339133252e6b4beaa2ea2d55b6ded051,
title = "Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention",
keywords = "LDL cholesterol, cardiovascular outcomes, guidelines, percutaneous coronary intervention, statin intolerance, statins",
author = "Rosenson, {Robert S.} and Colantonio, {Lisandro D.} and Goonewardena, {Sascha N.}",
note = "Funding Information: Dr. Rosenson has received research funding to his institution from Amgen, The Medicines Company, National Institutes of Health, Novartis, and Regeneron; has received consulting fees from Amgen, C5, Corvidia, CVS Caremark, The Medicines Company, Regeneron, and 89Bio; has received nonpromotional speaker fees from Amgen, Kowa, Pfizer, and Regeneron; has received royalties from Wolters Kluwer (UpToDate); has stock holdings in MediMergent; and holds a patent on biocellular inflammatory pathways. Dr. Colantonio has received research funding to his institution from Amgen. Dr. Goonewardena has reported that he has no relationships relevant to the contents of this paper to disclose.",
year = "2020",
month = sep,
day = "22",
doi = "10.1016/j.jacc.2020.07.050",
language = "English",
volume = "76",
pages = "1451--1454",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "12",
}